Table 2. Cox proportional hazards model for recurrence-free survival and overall survival (n = 262).

A. Univariate analysis
		Recurrence-free survival			Overall survival
Variable		HR	95% CI	P value	HR	95% CI	P value
Age	(50< vs. ≤50)	1.8	0.8–5.4	0.19	2.2	0.8–9.4	0.16
Tumor size	(2cm< vs. ≤2cm)	3.7	1.8–8.3	0.0003	3.9	1.7–10.2	0.002
Nodal status	(Positive vs. Negative)	4.4	2.1–9.4	<0.0001	4.3	1.9–10.7	0.0006
pStage	(III vs. I and II)	6.8	3.1–14.1	<0.0001	9.5	4.0–21.9	<0.0001
Nuclear grade	(3 vs. 1 and 2)	1.1	0.5–2.4	0.87	1.0	0.4–2.4	0.93
Ki-67	(20%< vs. ≤20%)	1.2	0.4–5.1	0.76	1.0	0.3–4.1	0.96
Basal-like status	(Basal-like vs. Non-basal-like)	0.9	0.3–2.9	0.78	1.3	0.4–8.1	0.72
BRCAness status	(BRCAness vs. Non-BRCAness)	2.6	1.1–7.8	0.03	3.1	1.1–13.2	0.04
Chemotherapy	(Anthra vs. Non-anthra)	0.4	0.2–1.6	0.19	0.4	0.1–2.6	0.29
	(Anthra vs. No Treatment)	0.8	0.4–1.9	0.64	0.3	0.1–0.8	0.02
B. Multivariate analysis
		Recurrence-free survival			Overall survival
Variable		HR	95% CI	P value	HR	95% CI	P value
pStage	(III vs. I and II)	9.5	4.1–21.1	<0.0001	21.3	7.7–60.1	<0.0001
BRCAness status	(BRCAness vs. Non-BRCAness)	3.3	1.3–10.1	0.008	6.3	1.9–29.0	0.002
Chemotherapy	(Anthra vs. Non-anthra)	0.2	0.1–0.7	0.02	0.1	0.02–0.7	0.03
	(Anthra vs. No Treatment)	0.6	0.2–1.3	0.17	0.2	0.1–0.4	0.0002

HR, hazard ratio; CI, confidence interval; vs., versus; Anthra, Anthracycline-based adjuvant chemotherapy; non-Anthra, Non-anthracycline-based adjuvant chemotherapy.